Thus, A2AR agonists are useful in treating asthma and chronic obstructive pulmonary disease by blocking the flooding of the bronchioalveolar space with white cells and suppressing the activation of inflammatory cells, thereby reducing the extent of immunosuppression. The gene discussed is ADORA2A; the disease is asthma.